These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28622999)

  • 61. [Progress in developing viral polynucleotide (DNA) vaccines].
    Gendon IuZ
    Vopr Virusol; 1999; 44(4):148-54. PubMed ID: 10500980
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Wish list for viral vaccinologists.
    Griffiths P
    Rev Med Virol; 2012 Sep; 22(5):281-4. PubMed ID: 22836674
    [No Abstract]   [Full Text] [Related]  

  • 63. Invoices and farmer interviews for vaccine-exposure measurement in turkey-broiler production.
    Chauvin C; Bouvarel I; Beloeil PA; Sanders P; Guillemot D
    Prev Vet Med; 2005 Jul; 69(3-4):297-308. PubMed ID: 15907576
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Research and development strategies, examples among new vaccines].
    Denis F; Ploy MC
    Ann Pharm Fr; 2009 May; 67(3):198-202. PubMed ID: 19446670
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New approaches in viral vaccine development.
    Brown F
    Scand J Infect Dis Suppl; 1990; 76():39-46. PubMed ID: 1966307
    [TBL] [Abstract][Full Text] [Related]  

  • 66. DNA vaccines for viral infections: basic studies and applications.
    Robinson HL; Pertmer TM
    Adv Virus Res; 2000; 55():1-74. PubMed ID: 11050940
    [No Abstract]   [Full Text] [Related]  

  • 67. Improving DNA vaccines targeting viral infection.
    Sin JI; Weiner DB
    Intervirology; 2000; 43(4-6):233-46. PubMed ID: 11251379
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Control of pediatric viral diseases: past successes and future prospects.
    Chanock RM
    Pediatr Res; 1990 Jun; 27(6 Suppl):S39-43. PubMed ID: 2113272
    [No Abstract]   [Full Text] [Related]  

  • 69. The interface of animal and human vaccines.
    Schmaljohn C; Mandl CW
    Curr Opin Virol; 2012 Jun; 2(3):306-8. PubMed ID: 22542098
    [No Abstract]   [Full Text] [Related]  

  • 70. [Use and effectiveness of multiple vaccines of life viruses].
    Villarejos VM
    Bol Oficina Sanit Panam; 1975 Feb; 78(2):132-7. PubMed ID: 126063
    [No Abstract]   [Full Text] [Related]  

  • 71. Vaccine Development.
    Woodland DL
    Viral Immunol; 2017 Apr; 30(3):141. PubMed ID: 28281914
    [No Abstract]   [Full Text] [Related]  

  • 72. Pathogenic epitopes, heterologous immunity and vaccine design.
    Welsh RM; Fujinami RS
    Nat Rev Microbiol; 2007 Jul; 5(7):555-63. PubMed ID: 17558423
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mucosal immunity to infections and its importance in future vaccinology.
    Lajeunesse M; Zhang Q; Finn A
    Adv Exp Med Biol; 2004; 549():13-22. PubMed ID: 15250511
    [No Abstract]   [Full Text] [Related]  

  • 74. Capripoxvirus-vectored vaccines against livestock diseases in Africa.
    Boshra H; Truong T; Nfon C; Gerdts V; Tikoo S; Babiuk LA; Kara P; Mather A; Wallace D; Babiuk S
    Antiviral Res; 2013 May; 98(2):217-27. PubMed ID: 23499648
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunological memory to viral infection.
    Slifka MK
    Curr Opin Immunol; 2004 Aug; 16(4):443-50. PubMed ID: 15245737
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vaccination status of children considered for renal transplants: missed opportunities for vaccine preventable diseases.
    Genc G; Ozkaya O; Aygun C; Yakupoglu YK; Nalcacioglu H
    Exp Clin Transplant; 2012 Aug; 10(4):314-8. PubMed ID: 22845763
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Viral vaccines: past successes and future challenges.
    Ahmed R; Burton DR
    Curr Opin Virol; 2013 Jun; 3(3):307-8. PubMed ID: 23809262
    [No Abstract]   [Full Text] [Related]  

  • 78. Recombinant viruses as vaccines against viral diseases.
    Souza AP; Haut L; Reyes-Sandoval A; Pinto AR
    Braz J Med Biol Res; 2005 Apr; 38(4):509-22. PubMed ID: 15962176
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The application of virus-like particles to human diseases.
    Buonaguro F; Buonaguro L
    Expert Rev Vaccines; 2013 Feb; 12(2):99. PubMed ID: 23414399
    [No Abstract]   [Full Text] [Related]  

  • 80. Vaccine development in the twenty-first century: changing paradigms for elusive viruses.
    Graham BS; Ledgerwood JE; Nabel GJ
    Clin Pharmacol Ther; 2009 Sep; 86(3):234-6. PubMed ID: 19707212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.